Contingent value rights are increasingly used in biotech deals to bridge price gaps amid market turbulence.#PharmaSignal #Biotech #MergersAndAcquisitions
Browsing: M&A and Licensing
News and insights on mergers, acquisitions, licensing deals, and strategic collaborations across the global pharma industry.
Biogen Dayra partnership aims to identify oral macrocycle candidates for high-priority immunological targets, enhancing Biogen’s immune portfolio.
Purdue Pharma settlement approved, Sacklers to pay $7 billion over 15 years to address opioid crisis.
Johnson & Johnson acquires Halda Therapeutics for $3.05 billion, marking a significant move in the PROTACs technology space.
Johnson & Johnson acquires Halda Therapeutics for $3.05 billion, enhancing its cancer treatment pipeline.
Alkermes Avadel bid increases as the company aims to strengthen its position in the US market.
Pfizer Metsera deal finalizes at $10 billion, enhancing Pfizer’s pipeline and market position.
Alkermes bidding war with Lundbeck over a sleepiness drug could impact its market strategy and financial outlook.
Novo Nordisk acquires Akero Therapeutics for $5.2 billion, enhancing its MASH treatment pipeline.
Chiesi Arbor partnership focuses on advancing gene editing therapies for rare diseases, targeting primary hyperoxaluria type 1.